

# **Dr. Maryam Niksolat**

## **Geriatrician**

**Assistant Professor of Geriatric Medicine**  
**Iran University of Medical Sciences**



*hypertension risk factors of cardiovascular disease ,stroke, chronic kidney disease, atrial fibrillation, congestive heart failure .(CHF, including diastolic dysfunction), cognitive.*

Lowering blood pressure by 10mmHg systolic and 5mmHg diastolic at age 65 years is with a reduction of up to 25% in myocardial infarction, 40% in stroke, 50%CHF, 10% to 20% overall decrease in mortality





Prevalence for hypertension aged 65 years or older ranges between 50% and 75%.



# •Age-Related Physiological Changes that Contribute to:Elevated Blood Pressure

- Arterial stiffness
- Decreased baroreceptor sensitivity
- Increased sympathetic nervous system activity
- Decreased alpha- and beta-adrenergic receptor responsiveness
- Endothelial dysfunction
- Decreased ability to excrete sodium load (sodium sensitivity)
- Low plasma renin activity
- Resistance to insulin's effect on carbohydrate metabolism
- Central adiposity





In the general nonblack population, including those with diabetes, initial treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).



-In the population ages 18 or older with CKD and hypertension, initial (or add-on) treatment should include an ACE inhibitor or an ARB to improve kidney outcomes.

-This applies to all patients in this population regardless of race or diabetes status





❖ main objective of hypertension treatment is to attain and maintain goal BP.

-If goal BP is not reached within a month of initiating treatment, increase the dose of the initial drug or add a

-second drug from one of these four classes.

The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached.

-If goal BP cannot be reached with two drugs, add and titrate a third drug from the list provided.



This final recommendation includes a caveat that ACE inhibitors and ARBs should not be used concomitantly.

If goal BP cannot be reached using the above-named drugs because of a contraindication or the need to use more than three such drugs to reach goal BP, antihypertensive drugs from other classes may be used.





- **hypertension :**


a person's systolic blood pressure (SBP) in the office or clinic is  $\geq 140$  mm Hg and/or their diastolic blood pressure (DBP) is  $\geq 90$  mm Hg following repeated examination.



- diagnosis should not be made on a single office visit.
- Usually 2–3 office visits at 1–4-week intervals (depending on the BP level) are required to confirm the diagnosis of hypertension.
- The diagnosis might be made on a single visit, if BP is  $\geq 180/110$  mm Hg and there is evidence of cardiovascular disease








- Quiet room, comfortable temperature
- No smoking, coffee, exercise for 30 min
- Empty bladder
- Relax for 3–5 min
- Take 3 measurements at 1 min intervals
- Use the average of the last 2 measurements

1 For manual auscultatory devices the inflatable bladder of the cuff must cover 75–100 % of the individual's arm circumference. For electronic devices use cuffs according to device instructions.

2 See validated electronic devices lists at [www.stridebp.org](http://www.stridebp.org)







**ESSENTIAL**

Target BP reduction by at least 20/10 mmHg, ideally to <140/90 mmHg

**OPTIMAL**

<65 years : BP target <130 / 80 mmHg if tolerated (but >120 / 70 mmHg).  
≥65 years : BP target <140 / 90 mmHg if tolerated but consider an individual-  
ised BP target in the context of frailty, independence and likely tolerability of  
treatment.

**Aim for  
BP control  
within 3 months**



Thiazide-type diuretics	<ul style="list-style-type: none"> <li>• Documented benefit in clinical trials</li> <li>• Produce greater reduction in systolic than diastolic blood pressure</li> <li>• Improve bone mineral density</li> <li>• Inexpensive</li> </ul>	<ul style="list-style-type: none"> <li>• Metabolic abnormalities (eg, hypokalemia)</li> <li>• Urinary frequency</li> </ul>	<ul style="list-style-type: none"> <li>• Systolic hypertension</li> </ul>	<ul style="list-style-type: none"> <li>• Hyponatremia</li> </ul>
				<ul style="list-style-type: none"> <li>• Gout</li> </ul>
ACE inhibitors and angiotensin receptor blockers	<ul style="list-style-type: none"> <li>• Absence of CNS effects</li> <li>• Preservation of renal function</li> <li>• Decrease proteinuria</li> </ul>	<ul style="list-style-type: none"> <li>• Hyperkalemia, cough</li> </ul>	<ul style="list-style-type: none"> <li>• CHF, type 2 diabetes</li> </ul>	<ul style="list-style-type: none"> <li>• Renal insufficiency or renal artery stenosis</li> </ul>
Calcium channel antagonists	<ul style="list-style-type: none"> <li>• Benefit documented in clinical trials</li> <li>• Absence of CNS or metabolic effects</li> </ul>	<ul style="list-style-type: none"> <li>• Peripheral edema, constipation, heart block</li> </ul>	<ul style="list-style-type: none"> <li>• Systolic hypertension</li> <li>• Coronary artery disease</li> </ul>	<ul style="list-style-type: none"> <li>• Left ventricular dysfunction</li> </ul>
$\beta$ -Adrenergic receptor antagonists	<ul style="list-style-type: none"> <li>• Not recommended as monotherapy</li> </ul>	<ul style="list-style-type: none"> <li>• May increase peripheral vascular resistance</li> <li>• Metabolic abnormalities</li> <li>• CNS effects</li> </ul>	<ul style="list-style-type: none"> <li>• Postmyocardial infarction</li> </ul>	<ul style="list-style-type: none"> <li>• COPD, peripheral vascular disease, heart block, glucose intolerance, type 2 diabetes, hyperlipidemia, depression</li> </ul>
$\alpha$ -Adrenergic receptor antagonists	<ul style="list-style-type: none"> <li>• Improve urinary symptoms in BPH</li> </ul>	<ul style="list-style-type: none"> <li>• Increased rate of CHF hospitalizations as monotherapy relative</li> </ul>	<ul style="list-style-type: none"> <li>• Prostatism</li> </ul>	<ul style="list-style-type: none"> <li>• Left ventricular dysfunction</li> </ul>



# Hypertensive Emergencies

- A hypertensive emergency is the association of substantially elevated BP with acute HMOD.
- Target organs include the retina, brain, heart, large arteries, and the kidneys.
- This situation requires rapid diagnostic workup and immediate BP reduction to avoid progressive organ failure. Intravenous therapy is usually required.
- The choice of antihypertensive treatment is predominantly determined by the type of organ damage.



## **Malignant hypertension:**

Severe BP elevation (commonly  $>200/120$  mm Hg) associated with advanced bilateral retinopathy (hemorrhages, cotton wool spots, papilledema).

## **Hypertensive encephalopathy:**

Severe BP elevation associated with lethargy, seizures, cortical blindness and coma in the absence of other explanations.





**Hypertensive thrombotic microangiopathy:** Severe BP elevation associated with hemolysis and thrombocytopenia in the absence of other causes and improvement with BP-lowering therapy.

Other presentations of hypertensive emergencies include severe BP elevation associated with cerebral hemorrhage, acute stroke, acute coronary syndrome, cardiogenic pulmonary edema, aortic aneurysm/dissection, and severe preeclampsia and eclampsia.



## Clinical Presentation and Diagnostic Workup:

- The clinical presentation of a hypertensive emergency can vary and is mainly determined by the organ(s) acutely affected. There is no specific BP threshold to define a hypertensive emergency.
- Symptoms include headaches, visual disturbances, chest pain, dyspnea, neurologic symptoms, dizziness, and more unspecific presentations.

Medical history: preexisting hypertension, onset and duration of symptoms, potential causes (nonadherence with prescribed antihypertensive drugs, lifestyle changes, concomitant use of BP elevating drugs [NSAIDs, steroids, immune-suppressants, sympathomimetics, cocaine, antiangiogenic therapy





# Diagnostic Tests and Acute Therapeutic Management

- ❖ The timeline and magnitude of BP reduction is strongly dependent on the clinical context.
- ❖ For example, acute pulmonary edema and aortic dissection require rapid BP reduction, whereas BP levels not exceeding 220/120 mm Hg are generally tolerated in acute ischemic stroke for certain periods.
- ❖ *provides a general overview of timelines and BP targets as well as preferred antihypertensive drug choices with most common clinical presentations.*



# Diagnostic Tests and Acute Therapeutic Management

- ❖ Availability of drugs and local experience with individual drugs are likely to influence the choice of drugs.
- ❖ Labetalol and nicardipine are generally safe to use in all hypertensive emergencies and should be available wherever hypertensive emergencies are being managed.
- ❖ Nitroglycerin and nitroprusside are specifically useful in hypertensive emergencies including the heart and the aorta.

